Clinical trials
Malignancy clinical trials
Below are recruiting malignancy clinical trials, each written for real people, not researchers. We’re tracking 1,585 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05131022RecruitingPhase 1
Study of NX-5948 for relapsed B-cell blood cancers
This Phase 1 study tests NX-5948 in adults whose B-cell cancers have come back or did not respond to prior treatment. It aims to find a safe dose and see how well the treatment works in different types of B-cell malignancies.
Duarte, CaliforniaAges 18 years+ - NCT05144698RecruitingPhase 1/Phase 2
RAPA-201 cell therapy for certain advanced lung and head cancers
This Phase 1/2 trial tests RAPA-201, a personalized immune cell treatment made from your own T cells, for advanced solid tumors. It may help people whose cancer has come back after standard treatment and after an anti–PD-1/PD-L1 antibody.
Hackensack, New JerseyAges 18 years+ - NCT05159245RecruitingPhase 2
Targeted drug access for adults with advanced cancer
This trial helps match people with advanced, hard-to-treat cancers to targeted cancer drugs based on lab testing of their tumor. It may help if standard treatment isn’t working or isn’t available, and if your tumor has a “targetable” genetic change.
Turku, Southwest FinlandAges 18–100 - NCT05170347Recruiting
Study of graft-versus-host disease after bone marrow transplant
This study follows people after an allogeneic bone marrow transplant to understand a complication called graft-versus-host disease. If you can attend follow-up visits, your experience and samples may be compared with a family control to look for differences.
Hong KongAges 18 years+ - NCT05179486Recruiting
Study genes and blood markers in bile duct and gallbladder cancers
This study looks at genetic and molecular patterns in people with bile duct or gallbladder cancers, and compares them with people without cancer (or with chronic liver disease). It may help researchers understand why these cancers happen and how to spot risk earlier.
Houston, TexasAges Any age - NCT05189054Recruiting
Radiation retreatment for very central chest tumors
This trial tests a focused form of radiation (SBRT) to treat tumors in the very center of the chest that have already been treated with radiation before. It aims to check safety and whether the tumor can be controlled without causing unacceptable side effects.
Beijing, Beijing MunicipalityAges 18–80 - NCT05211557RecruitingPhase 1/Phase 2
CAR-T therapy for recurrent ovarian cancer with B7H3
This Phase 1/2 study tests a personalized immune-cell treatment (fully human B7H3 CAR-T) for ovarian cancer that has come back or did not respond. It aims to see whether CAR-T can attack tumors that carry a target called B7H3.
Xuzhou, JiangsuAges 18–70 - NCT05226494RecruitingPhase 1
Test drug fb-PMT in recurrent brain cancer patients
This Phase 1 study tests how safe and tolerable fb-PMT is for people with glioblastoma that has come back. It also helps doctors learn the best way to give it and what side effects to watch for.
New Haven, ConnecticutAges 18 years+ - NCT05237986Recruiting
Study brain and thinking effects after CAR T therapy in youth
This study looks at how CAR T-cell treatment affects thinking, learning, and day-to-day brain function in children and young adults with certain blood cancers. You (and a caregiver) may complete online testing so researchers can track these changes over time and whether support is needed.
Los Angeles, CaliforniaAges 5 years+ - NCT05245500RecruitingPhase 1
Study drug for solid tumors with MTAP gene deletion
This Phase 1 trial studies MRTX1719, a new medicine, in solid tumors that have a missing MTAP gene (MTAP deletion). It aims to find the safest dose and check how the drug affects the tumor.
Phoenix, ArizonaAges 18 years+ - NCT05247268RecruitingPhase 2
Hormone therapy to shrink early uterine cancer in young women
This trial tests whether combining two hormone medicines can treat early endometrial (uterine) cancer while helping preserve the uterus and future fertility. You may be eligible if your cancer is early and limited, with no spread seen on scans, and you can safely take these medicines.
ShanghaiAges 18–45 - NCT05248763Recruiting
Cancer Moonshot program for specific cancer types
This study is for people with certain cancers: lung, breast, gastric (stomach), pancreatic, or ovarian. It aims to test a Moonshot-style approach to improve cancer care for these groups.
TaipeiAges 20 years+ - NCT05266612RecruitingPhase 1
Testing a cancer medicine for advanced solid tumors with HSV
This early (Phase 1) study tests VG2025, given alone or with nivolumab, in people with advanced solid cancers that have not responded to standard treatment. It may help by activating an immune response against cancer, especially in people who have HSV (herpes simplex virus) in their system.
Gilbert, ArizonaAges 18 years+ - NCT05271240RecruitingPhase 3
Targeted brain-artery drug added to standard treatment for new GBM
This Phase 3 trial tests whether delivering a cancer drug directly into brain blood vessels, along with standard radiation and temozolomide, works better than standard treatment alone in newly diagnosed glioblastoma (GBM). The goal is to improve control of the tumor while comparing side effects between the two approaches.
New York, New YorkAges 18 years+ - NCT05284877Recruiting
Study of HPV and skin cancer after organ transplant
This study looks at how human papillomavirus (HPV) and skin cancer behave in people who have had a solid organ transplant. It also includes healthy people for comparison, to understand what might be different after transplant and immune medicines.
Copenhagen NV, Capital RegionAges 18 years+ - NCT05292664RecruitingPhase 1
Venetoclax trial for high-risk blood cancers in young patients
This Phase 1 study tests venetoclax to treat certain high-risk blood cancers in children, teens, or young adults. It is designed to see if the drug can work safely for patients whose disease has returned or did not respond to prior treatment.
San Francisco, CaliforniaAges 1–40 - NCT05302037RecruitingPhase 1
CAR T cell therapy for advanced cancers that can be targeted
This early-phase study tests a lab-made immune cell treatment that is designed to find and attack tumors that show a specific target on cancer cells. It is for adults with advanced cancers that have not responded well to at least two standard treatments.
SingaporeAges 21 years+ - NCT05306509Recruiting
Early palliative care talks for kids with cancer
This trial tests whether nurse-led conversations about comfort and support (palliative care) early in a child’s cancer journey can help families and the child cope better. It is focused on newly diagnosed or relapsed pediatric cancer patients in Chinese-speaking settings.
Shanghai, MinhangAges Up to 18 years - NCT05307939RecruitingPhase 2
Using tumor DNA tests to time treatment for HPV throat cancer
This study checks a blood test that looks for HPV tumor DNA to help doctors decide when to start routine treatment after surgery. It may help some people avoid starting treatment too early or too late based on how the test changes after the operation.
Miami, FloridaAges 18 years+ - NCT05315167RecruitingPhase 1/Phase 2
Study drug PRJ1-3024 for advanced solid tumors
This trial tests how safe PRJ1-3024 is and how the body handles it, and it also looks for early signs that it can shrink advanced solid tumors. It may help people whose cancer can’t be treated with standard options.
Zhengzhou, HenanAges 18 years+ - NCT05327023RecruitingPhase 1/Phase 2
Donor immune cells after bone marrow transplant for high-risk blood cancers
This trial studies giving donor lymphocyte (immune) infusions after a bone marrow transplant for people with high-risk blood cancers. The goal is to help the immune system better fight the cancer and improve outcomes after transplant.
Bethesda, MarylandAges 12–120 - NCT05336383RecruitingPhase 2
Radiation after prior CAR T for relapsed multiple myeloma
This trial tests giving “salvage” radiation (radiation meant to control remaining cancer) after you’ve already had BCMA CAR-T therapy for multiple myeloma. It’s for people whose PET or other scan still shows active myeloma at least 30 days after CAR-T, and who have a spot that radiation can target.
Houston, TexasAges 18 years+ - NCT05371132RecruitingPhase 1
PET scan study to track immune response after SBRT
This early (Phase 1) study uses a special PET scan to measure how your immune system responds after stereotactic body radiation therapy (SBRT). The goal is to see whether the scan result can serve as a marker of immune response, which may help future treatment planning.
Duarte, CaliforniaAges 18 years+ - NCT05384288Recruiting
How kids with blood cancers respond to the flu vaccine
This study looks at how children with blood cancers respond to the seasonal flu shot. It may help doctors understand what protection the vaccine provides for pediatric oncology patients.
Memphis, TennesseeAges Up to 18 years
Hear when a new Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for malignancy?
- Yes. Clin2 currently lists 1,585 recruiting malignancy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a malignancy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a malignancy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.